FY2022 EPS Estimates for VolitionRx Limited (NYSEAMERICAN:VNRX) Raised by Analyst

VolitionRx Limited (NYSEAMERICAN:VNRXGet Rating) – Research analysts at Cantor Fitzgerald boosted their FY2022 earnings per share estimates for shares of VolitionRx in a research note issued on Tuesday, November 22nd. Cantor Fitzgerald analyst R. Osborn now forecasts that the medical research company will post earnings of ($0.59) per share for the year, up from their previous estimate of ($0.62). The consensus estimate for VolitionRx’s current full-year earnings is ($0.50) per share. Cantor Fitzgerald also issued estimates for VolitionRx’s FY2023 earnings at ($0.87) EPS.

Several other equities analysts have also commented on the company. Aegis reduced their price target on VolitionRx from $9.00 to $6.00 and set a “buy” rating on the stock in a research report on Monday, August 15th. Maxim Group reduced their price target on VolitionRx from $8.00 to $5.00 in a research report on Tuesday, August 23rd.

VolitionRx Price Performance

VolitionRx stock opened at $2.23 on Thursday. The company has a market cap of $127.77 million, a P/E ratio of -4.85 and a beta of 1.73. The company has a current ratio of 4.17, a quick ratio of 4.17 and a debt-to-equity ratio of 0.12. VolitionRx has a one year low of $1.31 and a one year high of $3.72.

Hedge Funds Weigh In On VolitionRx

A number of institutional investors have recently made changes to their positions in the business. BlackRock Inc. raised its position in shares of VolitionRx by 1.0% in the 1st quarter. BlackRock Inc. now owns 547,862 shares of the medical research company’s stock valued at $1,650,000 after purchasing an additional 5,644 shares in the last quarter. State Street Corp raised its position in shares of VolitionRx by 10.0% in the 1st quarter. State Street Corp now owns 115,323 shares of the medical research company’s stock valued at $347,000 after purchasing an additional 10,500 shares in the last quarter. Captrust Financial Advisors raised its position in shares of VolitionRx by 316.7% in the 1st quarter. Captrust Financial Advisors now owns 25,000 shares of the medical research company’s stock valued at $75,000 after purchasing an additional 19,000 shares in the last quarter. Cowen Prime Advisors LLC raised its position in shares of VolitionRx by 27.5% during the 3rd quarter. Cowen Prime Advisors LLC now owns 96,631 shares of the medical research company’s stock valued at $131,000 after acquiring an additional 20,831 shares in the last quarter. Finally, Virtu Financial LLC acquired a new stake in shares of VolitionRx during the 3rd quarter valued at approximately $51,000. 11.49% of the stock is owned by institutional investors and hedge funds.

About VolitionRx

(Get Rating)

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes.

Further Reading

Earnings History and Estimates for VolitionRx (NYSEAMERICAN:VNRX)

Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with MarketBeat.com's FREE daily email newsletter.